Across TCGA pan-cancer cohorts, CDC123 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CDC123 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CDC123 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDC123 expression acts as an unfavorable survival marker.
LUAD and UCEC are the cancer types where CDC123 Mutation most reproducibly stratifies survival.